Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)

OBJECTIVE: In the primary analysis of the phase 2b VESTA study, oral fezolinetant reduced frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo. This secondary analysis evaluates effects of fezolinetant on responder rates and patient-reported outcomes (PROs). METHODS: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoro, Nanette, Waldbaum, Arthur, Lederman, Samuel, Kroll, Robin, Fraser, Graeme L., Lademacher, Christopher, Skillern, Laurence, Young, James, Ramael, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709922/
https://www.ncbi.nlm.nih.gov/pubmed/32769757
http://dx.doi.org/10.1097/GME.0000000000001621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709922/
https://www.ncbi.nlm.nih.gov/pubmed/32769757
http://dx.doi.org/10.1097/GME.0000000000001621

Ejemplares similares